# BridgeBio

BridgeBio is an Asset Manager based in Palo Alto, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Palo Alto, United States
- **Region:** North America
- **Address:** Palo Alto, CA, United States
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** bridgebio.com
- **LinkedIn:** https://www.linkedin.com/company/bridgebio

## Regulatory record

- **Reports private funds:** No

## About

BridgeBio, headquartered in Palo Alto, United States, was established in 2014. The firm focuses on developing early-stage genetic disease assets through its proprietary platform and management expertise. It has secured $724 million in total funding.

## Sectors

- Biotechnology
- Pharmaceuticals
- Rare Disease Therapeutics

## People

- Neil Kumar — Founder & CEO
- Eric Hedrick — Chief Medical Officer

## Questions

### How does BridgeBio's subsidiary model affect its risk profile?

BridgeBio structures each therapeutic program as a separate subsidiary, which limits liability to individual assets and preserves the parent company's balance sheet. This allows the firm to pursue multiple high-risk programs concurrently. It also enables spinning out assets into independent companies if they progress to late stages, as seen with acoramidis.

### What sources of funding has BridgeBio used?

BridgeBio has raised over $2 billion through a combination of venture capital, IPO proceeds, and debt financing. The firm went public on Nasdaq in 2019. It has also raised capital via milestone payments and partnerships, including a royalty deal with Blueprint Medicines in 2024. BridgeBio has not disclosed any direct family office or sovereign wealth fund backing.

### Has BridgeBio received any FDA approvals?

Yes. In November 2024, the FDA approved BridgeBio's acoramidis (branded Attruby) for the treatment of transthyretin amyloidosis with cardiomyopathy. This marked the firm's first regulatory approval and a key validation of its drug development model.

### What therapeutic areas does BridgeBio focus on?

BridgeBio's pipeline spans oncology, cardiology, and rare genetic diseases. The firm targets conditions such as transthyretin amyloidosis, achondroplasia, and various cancers. It uses genetic validation to identify high-probability targets and builds subsidiaries around each mechanism.

### Who leads investment decisions at BridgeBio?

Neil Kumar, founder and CEO, oversees corporate strategy and capital allocation. The firm's management team includes Eric Hedrick as Chief Medical Officer and experienced drug developers. As a publicly traded company, BridgeBio's board of directors also plays a role in major investment and partnership decisions.

## Related profiles

- [Chesapeake Urology Associates](https://altss.com/profile/chesapeake-urology-associates)
- [Global Employment Solutions](https://altss.com/profile/global-employment-solutions)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/bridgebio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology